The Designing Safer Medicines in Discovery conference and exhibition (http://www.soci.org/General-Pages/Display-Event?EventCode=FCHEM310) brought together over 100 delegates from Pharma, Academia and CROs to discuss the emerging opportunities for reducing drug attrition. In the 1990s, issues with pharmacokinetics and drug metabolism were the major cause of drug failure in clinical development, but the industry has since put in place successful strategies to reduce the impact of ADME/DMPK. Now, drug toxicity has come to the fore, leading to an increased focus on drug safety and the development of early screening procedures to detect and mitigate its effects.
- searching by keyword or phrase
- viewing assertions
- viewing properties and related terms of the word or phrase that you searched for
- searching by chemical structures, sub-structures and Tanimoto similarity searching
- the use of term lists for querying multiple terms
- advanced searches. for example, what compounds with a carboxylic sub-structure are known to cause cholestasis?
- viewing the original source document
- exporting data
The tour takes just under 3 minutes to run. Use the controls at the bottom of the screen to pause or rewind the video.
|Safety Intelligence Program Overview|
The Assertional Metadata (AMD) contained within our Safety Intelligence Program (SIP) represents the largest ever-expanding collection of known effects of chemicals occurring in the different tissue, drugs effects on clinical biomarkers of tissue injury and drug molecular mechanisms.